ELTX · NASDAQ · Biotechnology

Elicio Therapeutics (ELTX)

Develops AMP-enabled cancer immunotherapies centered on the ELI-002 mutant-KRAS program.

$1.88
vs last close+0.01 (+0.53%)

Something off on this page? Send us feedback.

Next report
Nov 12, 26
estimated · in 50 days
EPS estimate
−$0.52
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$1.02−$0.87−$0.66−$0.60−$0.49−$0.65−$0.43Pending
Estimate−$0.94−$0.67−$0.69−$0.62−$0.47−$0.49−$0.54−$0.52
Surprise−8.5%−29.9%+4.3%+3.2%−4.3%−32.7%+20.0%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$1.2MPending
Estimate
Surprise

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2027−$0.62
Sep 2027−$0.62
Jun 2027−$0.61
Mar 2027−$0.54
Dec 2026−$0.46
Nov 2026−$0.52
Aug 2026−$0.54−$0.43+20.0%
May 2026−$0.49−$0.65−32.7%
Mar 2026−$0.47−$0.49−4.3%
Nov 2025−$0.62−$0.60+3.2%
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Dec 2022
Nov 2022
Aug 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Mar 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020
Dec 2019

The latest year is open to everyone — the 25 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2027−$0.62$0
Sep 2027−$0.62$0
Jun 2027−$0.61$0
Mar 2027−$0.54$0
Dec 2026−$0.46$0
Nov 12, 2026−$0.52$0
Aug 13, 2026−$0.54−$0.43+20.0%−1.9%
May 11, 2026−$0.49−$0.65−32.7%+17.2%
Mar 12, 2026−$0.47−$0.49−4.3%−7.6%
Nov 13, 2025−$0.62−$0.60+3.2%−2.2%
Aug 7, 2025
May 13, 2025
Mar 31, 2025
Nov 13, 2024
Aug 13, 2024
May 15, 2024
Mar 29, 2024
Nov 9, 2023
Aug 11, 2023
May 10, 2023
Mar 17, 2023
Dec 31, 2022
Nov 14, 2022
Aug 15, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 29, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020
Dec 31, 2019

The latest year is open to everyone — the 25 quarters behind it read with an account.